Related Experiment Video
Updated: Sep 10, 2025

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
[Clinical study on low-dose rituximab maintenance therapy in children with primary nephrotic syndrome]
1Department of Renal Immunology, Children's Hospital of Soochow University, Suzhou, Jiangsu 215000, China.
Insights
Low-dose rituximab (RTX) maintenance therapy effectively treats pediatric primary nephrotic syndrome (PNS), maintaining remission and reducing relapses. This safe treatment option also lowered steroid and tacrolimus use in children.
Area of Science:
- Pediatric Nephrology
- Clinical Immunology
- Pharmacology
Context:
- Primary nephrotic syndrome (PNS) is a significant cause of kidney disease in children.
- Current treatments often involve long-term immunosuppression with potential side effects.
- Rituximab (RTX) has emerged as a potential therapeutic option for refractory PNS.
Purpose:
- To evaluate the clinical efficacy and safety of low-dose RTX maintenance therapy in pediatric patients with PNS.
- To assess the impact of low-dose RTX on remission rates, relapse frequency, and the need for other immunosuppressants.
Summary:
- A retrospective analysis of children with PNS treated with low-dose RTX (<375 mg/m²) was performed.
- Results showed that low-dose RTX significantly maintained remission, reduced relapse frequency, and decreased the requirement for corticosteroids and tacrolimus (P<0.05).
- Immunoglobulin G (IgG) levels remained stable, and no additional anti-infective prophylaxis was necessary.
Impact:
- Low-dose RTX maintenance therapy offers an effective and safe treatment strategy for pediatric PNS.
- This approach may reduce the cumulative burden of immunosuppression and associated toxicities in children with PNS.
- Findings support the use of rituximab as a valuable tool in managing pediatric nephrotic syndrome.
Objectives:
To investigate the clinical efficacy and safety of low-dose rituximab (RTX) (<375 mg/m²) maintenance therapy in children with primary nephrotic syndrome (PNS).
Methods:
A retrospective analysis was conducted on the clinical data of PNS children who received low-dose RTX therapy at the Department of Renal Immunology, Children's Hospital of Soochow University from July 2016 to March 2024. Remission rate, recurrence frequency, corticosteroid and tacrolimus usage, and adverse reactions before and after RTX treatment were analyzed.
Results:
Compared with before treatment, low-dose RTX maintained remission in PNS, reduced the relapse frequency, and decreased the dosage of corticosteroids and tacrolimus (P<0.05). IgG levels did not significantly decrease, and no additional preventive anti-infective treatment was required.
Conclusions:
Low-dose RTX therapy is effective and safe for treating PNS in children.
Related Concept Videos
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome I : Introduction
Continuous Renal Replacement Therapy
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
Chronic Kidney Disease III: Interprofessional Care

